About / the publisher
About this PT-141 digest
An independent editorial project that summarizes the published bremelanotide literature and the approved label — and is explicit about what it is not.
What Meds PT-141 is
Meds PT-141 is an independent editorial project that publishes summaries of the peer-reviewed research literature and the approved drug label on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The "meds" in the name is editorial framing — a position this publisher occupies relative to the literature on an approved medication, not a claim that the site provides medications, treatment, consultation, or prescriptions. It does none of those things. It reads the record and reports it.
Is PT-141 FDA-approved?
Yes, for one indication. Bremelanotide was approved by the FDA on June 21, 2019 (NDA 210557) as a subcutaneous injection for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. It is not approved for men, for postmenopausal women, for erectile dysfunction, or to enhance sexual performance — every use beyond the single approved indication is off-label and rests on early-phase or investigational data [6][14]. Material sold as "PT-141 research chemical" sits outside that approval framework entirely, with no regulatory oversight of its identity, purity, or concentration.
One further status note: melanocortin receptor agonists fall under the World Anti-Doping Agency's non-approved-substances framework (S0) in the relevant context, so athletes should consult current WADA guidance directly. PT-141 is not a US controlled or scheduled substance.
How we handle the record
Two principles govern this digest. First, evidence tiers are kept visible: the FDA label and the peer-reviewed Phase 3 trials carry the most weight, conference abstracts and corporate press releases are flagged as lower-tier, and we report the findings that complicate the picture (including a 2025 negative preclinical result) alongside the supportive ones [10]. Second, the cited clinical record and informal community reports are kept in separate, clearly-labeled layers — anything anecdotal is marked as unverified and is never attributed to a study. We summarize doses only as documented findings and recommend none. Every quantitative claim on this site links to a source in the studies and references.
We also try to be plain about the limits of what is known. The strongest evidence concerns one population and one indication; the male, erectile, postmenopausal, and weight-related threads are early-phase or off-label, and we label them that way every time they appear rather than letting interest in a topic inflate the certainty of the data behind it [14]. Where a finding is a single conference abstract, we say so. Where a number comes from a corporate pipeline announcement, we treat it as a development status and not a result. The aim is a record a careful reader can trust precisely because it does not oversell — the bright surface of this site is a reading console, never a sales page, and the negative-space between "approved for this" and "studied for that" is kept visible on purpose.